GB202103164D0 - Therapy - Google Patents

Therapy

Info

Publication number
GB202103164D0
GB202103164D0 GBGB2103164.6A GB202103164A GB202103164D0 GB 202103164 D0 GB202103164 D0 GB 202103164D0 GB 202103164 A GB202103164 A GB 202103164A GB 202103164 D0 GB202103164 D0 GB 202103164D0
Authority
GB
United Kingdom
Prior art keywords
therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2103164.6A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Adiga Life Sciences Inc
Original Assignee
Adiga Life Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adiga Life Sciences Inc filed Critical Adiga Life Sciences Inc
Priority to GBGB2103164.6A priority Critical patent/GB202103164D0/en
Publication of GB202103164D0 publication Critical patent/GB202103164D0/en
Priority to PCT/GB2022/050593 priority patent/WO2022189775A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/363—Fibrinogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
GBGB2103164.6A 2021-03-08 2021-03-08 Therapy Ceased GB202103164D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB2103164.6A GB202103164D0 (en) 2021-03-08 2021-03-08 Therapy
PCT/GB2022/050593 WO2022189775A1 (en) 2021-03-08 2022-03-07 Citrullinated or glutamine analogue peptide for use in preventing or treating rheumatoid arthritis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2103164.6A GB202103164D0 (en) 2021-03-08 2021-03-08 Therapy

Publications (1)

Publication Number Publication Date
GB202103164D0 true GB202103164D0 (en) 2021-04-21

Family

ID=75472492

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2103164.6A Ceased GB202103164D0 (en) 2021-03-08 2021-03-08 Therapy

Country Status (2)

Country Link
GB (1) GB202103164D0 (en)
WO (1) WO2022189775A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024117967A1 (en) * 2022-12-01 2024-06-06 Dubnovitsky Anatoly Peptide mimics and their use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9493539B2 (en) * 2003-03-07 2016-11-15 London Health Sciences Centre Research Inc. Peptides associated with HLA-DR MHC class II molecules involved in autoimmune diseases
WO2006048556A1 (en) * 2004-11-04 2006-05-11 Biomerieux Citrulline peptides derived from fibrin and recognised by rheumatoid arthritis specific autoantibodies and the use thereof
ES2307421B1 (en) * 2007-04-30 2009-09-28 Consejo Superiorde Investigaciones Cientificas (Csic) CITRUINATED FIBRINE-FILAGRINE CHEMERIC POLYPEPTIDE CAPABLE OF DETECTING ANTIBODIES GENERATED IN REUMATOID ARTHRITIS.
EP2332987A1 (en) * 2009-12-10 2011-06-15 ModiQuest B.V. Anti-inflammatory agents directed against citrullinated epitopes
IL303425A (en) * 2013-03-13 2023-08-01 Cour Pharmaceuticals Dev Company Immune-modifying particles for the treatment of inflammation

Also Published As

Publication number Publication date
WO2022189775A1 (en) 2022-09-15

Similar Documents

Publication Publication Date Title
GB202001980D0 (en) Therapeutic mentods
GB202004189D0 (en) Combination therapy
GB202006960D0 (en) Therapeutic
GB202108303D0 (en) Therapy
GB202111288D0 (en) Combination therapy
GB202103164D0 (en) Therapy
EP4225129A4 (en) Oct guided therapy
GB202117706D0 (en) Therapy
GB202111035D0 (en) Therapy
GB202109893D0 (en) PeptiBAC therapy
GB202104427D0 (en) Therapy
GB202102211D0 (en) PeptiBAC therapy
GB202019218D0 (en) Therapy
GB202017598D0 (en) Therapy
GB202017554D0 (en) Therapy
GB202015780D0 (en) Therapy
GB202015778D0 (en) Therapy
GB202013834D0 (en) PeptiVAX therapy
GB202013824D0 (en) PeptiBAC therapy
GB202009039D0 (en) Therapy
GB202008031D0 (en) Therapy
GB202004629D0 (en) Therapy
GB202004013D0 (en) Therapy
GB202002639D0 (en) Therapy
GB202001905D0 (en) Therapy

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)